Skip to main content
Debate: First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs. VEGF Inhibitors: EGFR Inhibitors.
Thursday, September 23, 2021
1:30 PM – 1:38 PM
Josep Tabernero, MD
Vall d’Hebron University Hospital
This talk is supported by educational grants provided by Bayer HealthCare Pharmaceuticals, Inc., Pfizer
Inc. and Taiho Oncology, Inc.